Page last updated: 2024-12-10
ssya10-001
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
SSYA10-001: a helicase inhibitor with antiviral activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 2807230 |
| CHEMBL ID | 1595621 |
| SCHEMBL ID | 15398584 |
| MeSH ID | M000609781 |
Synonyms (31)
| Synonym |
|---|
| smr000567368 |
| MLS001181552 , |
| SR-01000635060-1 |
| 3-[(2-nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1h-1,2,4-triazole-5-thione |
| HMS2884A17 |
| CCG-45281 |
| CHEMBL1595621 , |
| SCHEMBL15398584 |
| 3-[[(2-nitrophenyl)thio]methyl]-4-prop-2-enyl-1h-1,2,4-triazole-5-thione |
| cid_2807230 |
| 4-allyl-3-[[(2-nitrophenyl)thio]methyl]-1h-1,2,4-triazole-5-thione |
| bdbm61876 |
| dshs00884 |
| CS-0065749 |
| HY-113794 |
| ssya10-001 |
| 675104-49-1 |
| MS-24471 |
| 3-[(2-nitrophenyl)sulphanylmethyl]-4prop-2-enyl-1h-1,2,4-triazole-5-thione |
| 3h-1,2,4-triazole-3-thione, 2,4-dihydro-5-(((2-nitrophenyl)thio)methyl)-4-(2-propen-1-yl)- |
| 2,4-dihydro-5-(((2-nitrophenyl)thio)methyl)-4-(2-propen-1-yl)-3h-1,2,4-triazole-3-thione |
| 3-((2-nitrophenyl)sulfanylmethyl)-4-prop-2-enyl-1h-1,2,4-triazole-5-thione |
| ssya-10-001 |
| 3h-1,2,4-triazole-3-thione, 2,4-dihydro-5-(((2-nitrophenyl)thio)methyl)-4-(2-propenyl)- |
| dc9cuh9ljy , |
| 3-((2-nitrophenyl)sulfanylmethyl)-4-(prop-2-enyl)-1h-1,2,4-triazole-5-thione |
| ssya 10-001 |
| unii-dc9cuh9ljy |
| DTXSID201320083 |
| bdbm50596957 |
| AKOS040741674 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (26)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 16.8336 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 31.6228 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 8.9125 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| WRN | Homo sapiens (human) | Potency | 39.8107 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 35.4813 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| GLS protein | Homo sapiens (human) | Potency | 17.7828 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 15.8489 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 2.5119 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 50.1187 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 39.8107 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.2589 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 100.0000 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 10.0000 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 65.9602 | 0.1337 | 25.4129 | 89.1251 | AID588795; AID720498 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 11.9173 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 18.2617 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 31.0726 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 50.1187 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 44.6684 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Myeloid cell leukemia sequence 1 (BCL2-related) | Homo sapiens (human) | IC50 (µMol) | 29.5850 | 0.4415 | 3.7529 | 5.4780 | AID2217 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 2.2400 | 0.2700 | 26.3638 | 100.0000 | AID504719 |
| DNA dC->dU-editing enzyme APOBEC-3A isoform a | Homo sapiens (human) | IC50 (µMol) | 38.9000 | 1.4800 | 14.5267 | 61.2000 | AID504722 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 1.5230 | 0.0002 | 2.4585 | 9.9600 | AID1880214; AID1880216 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (20)
Molecular Functions (14)
Ceullar Components (9)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cortical actin cytoskeleton | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| microvillus | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| endomembrane system | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| lamellipodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| filopodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| extracellular exosome | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| double membrane vesicle viral factory outer membrane | Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (23)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1718101 | Inhibition of SARS-CoV NSP13 helicase K508A mutant using Cy3-labeled 31/18-mer as substrate measured after 10 min by FRET-based assay | 2020 | Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22 | Druggable targets from coronaviruses for designing new antiviral drugs. |
| AID1718077 | Inhibition of SARS-CoV NSP13 helicase Y277A mutant using Cy3-labeled 31/18-mer as substrate measured after 10 min by FRET-based assay | 2020 | Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22 | Druggable targets from coronaviruses for designing new antiviral drugs. |
| AID1880214 | Inhibition of SARS-CoV-2 nsp13 helicase-associated activity using 5'- AGT CTT CTC CTG GTG CTC GAA CAG TGA CCy3-3', 5'- BHQ-2-GTC ACT GTT CGA GCA CCA CCT CTT CTG A-3' DNA as substrate preincubated for 10 mins followed by substrate addition and measured aft | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
| AID1718100 | Inhibition of SARS-CoV NSP13 helicase using fluorescein and black hole quencher labelled dsDNA as substrate measured after 10 min by FRET-based assay | 2020 | Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22 | Druggable targets from coronaviruses for designing new antiviral drugs. |
| AID1718076 | Inhibition of SARS-CoV wild type NSP13 helicase using Cy3-labeled 31/18-mer as substrate measured after 10 min by FRET-based assay | 2020 | Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22 | Druggable targets from coronaviruses for designing new antiviral drugs. |
| AID1880217 | Inhibition of SARS-CoV-2 nsp13 ATPase-associated activity using ATP as substrate at highest concentration of compound incubated for 30 mins by Biomol Green Reagent based assay | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
| AID1880216 | Inhibition of SARS-CoV-2 nsp13 ATPase-associated activity using ATP as substrate incubated for 30 mins by Biomol Green Reagent based assay | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.23
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.23) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (15.38%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (84.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||